The first new non-opioid for severe acute pain has been on the market for a few months. But it's a lot more expensive than opioids, and many people can't get it because of spotty insurance coverage.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...